Novo A/S announces an expansion of its large investment portfolio through an investment in ERT alongside Nordic Capital Fund VIII.
ERT is the leading provider of high-quality electronic data collection solutions for clinical drug development programs, and their systems are widely used by pharmaceutical and biotech companies innovating drug and device therapies. Headquartered in Philadelphia, PA, Unites States, the company and its 1200 employees support more than 1500 clinical trials globally, capturing in excess of 400,000 patients, on an annual basis. ERT delivers a unique combination of technology, services and clinical consulting, built on a foundation of deep scientific and regulatory expertise. ERT’s solutions increase the accuracy and reliability of the patient data collected in healthcare areas such as cardiac safety and respiratory function as well as within electronic clinical outcome assessments.